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Abstract
Rhabdomyosarcoma, the most common pediatric soft
tissue sarcoma, likely results from deregulation of the
skeletal myogenesis program. Although associations
between PAX3, PAX7, FOXO1A, and RMS tumorigenesis
are well recognized, the entire spectrum of genetic
factors underlyingRMSdevelopment andprogression is
unclear. Using a combined approach of spectral karyo-
typing, array-based comparative genomic hybridization
(CGH), andexpressionanalysis,weexamined10primary
RMS tumors, including embryonal, alveolar, and the rare
adult pleomorphic variant, to explore the involvement of
different genes and genetic pathways in RMS tumori-
genesis. A complete karyotype established for each
tumor revealed a high aneuploidy level, mostly tetra-
ploidy, with double minutes and additional structural
aberrations. Quantitative expression analysis detected
the overexpression of the AURKA gene in all tumors
tested, suggesting a role for this mitotic regulator in the
aneuploidy and chromosomal instability observed in
RMS. Array-based CGH analysis in primary RMS tumors
detected copy number changes of genes involved in
multiple genetic pathways, including transcription fac-
tors such asMYC-related gene from lung cancer and the
cytoskeleton and cell adhesion–encoding genes lam-
inin g-2 and p21-activated kinase-1. Our data suggest
the involvement of genes encoding cell adhesion, cyto-
skeletal signaling, and transcriptional and cell cycle
components in RMS tumorigenesis.
Neoplasia (2006) 8, 332–343
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Introduction
Rhabdomyosarcoma (RMS), the most common pediatric
soft tissue sarcoma, likely results from an imbalance in the
proliferation and differentiation of precursor cells during the
skeletal myogenesis program. In contrast to normal myo-
blasts, which fuse into myotubes to form multinucleate
syncytial cells that no longer proliferate [1], RMS cells are
unable to reach terminal differentiation, exhibiting interrupted
myogenesis with sustained proliferation [2,3]. The tumor
seems to recapitulate normal embryonal myogenesis, express-
ing muscle-specific markers, such as MyoD and vimentin, that
are normally present during the different steps of fetal muscle
development [4,5]. The exact cell type from which RMS is
derived remains unclear; however, evidence of RMS in sites
other than the skeletal muscle suggests that the tumor may
originate from a primitive mesenchymal cell or from a commit-
ted myogenic precursor [2,3].
RMS tumors are classified into three subtypes according to
histopathological description: the more prevalent embryonal
rhabdomyosarcoma (ERMS), the more aggressive alveolar
rhabdomyosarcoma (ARMS), and the rare adult variant pleo-
morphic rhabdomyosarcoma (PRMS) [6]. Karyotype de-
scriptions of pleomorphic subtype are scarce, and only a few
chromosomal and genetic characteristics have been reported.
The two other RMS subtypes, ERMS and ARMS, often dem-
onstrate a high level of aneuploidy and are associated with
different cytogenetic changes [7,8]. Frequent but neither con-
sistent nor specific chromosomal gains nor losses are de-
tected in ERMS [9]. In contrast, the majority (about 85%) of
ARMS tumors are characterized by recurrent translocation
between the genes encoding for the transcription factors
FOXO1A (original name, FKHR, localized at chromosome
13q14) with either PAX3 (at 2q35) or, less commonly, PAX7
(at 1p36) [10]. PAX3 and PAX7 are also overexpressed in
some ARMS and ERMS tumors [11]. Chromosome instability
in RMS karyotypes is also reflected as genomic amplifica-
tion through double minutes (dmins) [12,13], which include
various genes such as MDM2, MYCN, and GLI, and the char-
acteristic ARMS fusion gene PAX3–FOXO1A or PAX7–
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FOXO1A [14–17]. Furthermore, conventional comparative
genomic hybridization (CGH) studies of primary RMS tumors
have confirmed quantitative genomic alterations of large
chromosomal regions, including the amplification of 2q and
8p or the deletion of 17p, as seen in cytogenetic analyses
and in the amplification and deletion of novel loci (15q25–
26[9] and 5q32-ter[7]). Additionally, other genes and path-
ways, such as IGF, SHH, and Rac1, have been implicated in
RMS tumorigenesis [2,18].
Materials and Methods
Primary Tumor Tissues and Cell Lines
Ten primary RMS tumors, including two ERMS, seven
ARMS, and one PRMS, were analyzed. Fresh non-necrotic
tissues were obtained during open biopsy or excision of the
tumor. All patients underwent systemic intravenous neoadju-
vant chemotherapy before excision, with the exception of
ARMS5 and PRMS1, which did not receive chemotherapy
before excision. ERMS2, which was a recurrent tumor, was
treated with neoadjuvant chemotherapy at the time of first
diagnosis, followed by radiotherapy. Routine cytogenetic
and pathological analyses were performed, and the diag-
nosis of RMS was confirmed according to standard clinical
criteria and pathological studies. The study was approved
by the IRB Helsinki Committees of the Tel-Aviv Sourasky
Medical Center and the Supreme National Helsinki Com-
mittee for Genetic Studies of the Israeli Ministry of Health.
Table 1 lists clinical and pathological features.
The RMS cell lines RD and A-204 (embryonal subtype)
were obtained from the American Type Culture Collection
(Manassas, VA). The RMS cell lines RH28 and RMZ-RC2
(alveolar subtype) were kindly provided by Dr. Peter J.
Houghton (St. Jude’s Children’s Research Hospital, Memphis,
TN) and Dr. Pier-Luigi Lollini (Department of Experimental
Pathology, University of Bologna, Bologna, Italy), respectively.
As normal controls, we purchased four different RNA
samples that were extracted from normal adult skeletal
muscles (Clontech BD Biosciences, Erembodegem, Bel-
gium; Ambion, Inc., Austin, TX; BioChain Institute, Inc.,
Hayward, CA).
Chromosomal Studies
Chromosomal analysis was performed on primary cul-
tures derived from all RMS samples. Short-term cultures,
chromosomal preparations, G-band staining, and spectral
karyotype (SKY) analysis were performed according to stan-
dard cytogenetic techniques and manufacturer’s instruc-
tions, as previously described [19]. SKY painting for ERMS1,
ARMS1, ARMS2, ARMS5, ARMS6, and PRMS1 samples
helped refine G-band findings and defined the origin of dmins.
Karyotypes were established according to the International
System for Human Cytogenetic Nomenclature [20].
Table 1. Clinical and Pathological Features and Cytogenetic Analyses of Primary RMS Cases.
RMS
Number
Age at
Biopsy
(years)/Sex
Primary Site/LNM Stage at Presentation
Intergroup
Rhabdomyosarcoma
Study
Outcome until
December 2005
Karyotype Descriptions
ERMS1 1/F Arm Group 1, stage 1 NED 46,XX,+2,8,der(17)t(11;17)(q13;p13),der(19)t(19;8)(q13.4;?),der(22)
t(19;22)(?;q13)t(8;19)(q?11.2;?)[6]/47,idem,+7[7]/48,idem,+7,+9[1]/
46,XX[2]*
ERMS2 7/M Leg and thigh/LNM Group 2, stage 1 D 46, Complex karyotypey
ARMS1 1/M Bilateral groins/LNM Group 3 D 83f85,XXYY,+i(1)(q10),t(2;12)(p?14;q23)x2,i(3)(q10),der(3)del(p24)t(3;17)
(q13;?),der(4)t(4;11)(p12;?)x2,der(5)t(5;12)(q12;?)x2,der(8)t(4;8)(?;p12),
9,9,+der(10)t(2;10)(?;p?),11,del(12)(q13q21)x2,del(13)(q14)x2,15,
15,del(17)(q22),17,21,2 dmin (3)[cp17]/46,XY[5]*
ARMS2 2/F Arm Group 1, stage 1 NED 92,XXXX,10f30 dmin (13)[7]/46,XX[10]*
ARMS3 3/M Perineum Group 2, stage 1 D 46,XY[15]y
ARMS4 17/F Hand Group 1, stage 1 NED 46,XX[25]y
ARMS5 18/M Thigh/LNM Group 1, stage 1 D 92,XXYY,del(13)(q14)x2,der(20)t(13;20)(q14;q13.3)x2,10f30 dmin
(13)[12]/46,XY[5]*
ARMS6 24/M Groin/LNM Group 2, stage 1 D 100f104<4n>,XXXYYY,+2,3,+5,+6,+6,+7,+8,+8,+8,+8,9,+10,11,
11,+12,+12,+12,17,19,19,+20,+22,+22,+22,20f30 dmin
(1)[10]/46,XY[5]*
ARMS7 31/F Perineum/LNM Group 2, stage 1 D 46,XX[15]y
PRMS1 68/M Groin/LNM Group 2, stage 1 D 74f82,XXY,del(1)(p11)x2+idic(1)(q10),del(2)(p1?6)x2,del(3)(q13)x2,4,
der(4)t(4;16)(p11;p11),der(4)t(4;17)(q28;q11),del(5)(p13),
+der(5)t(5;6)(q?35;?),der(5)t(5;10)(q3?4;q?21),del(6)(p?12),+i(6)
(q10),+der(6)t(6;6)(q2?5;q?),der(7)t(6;7),der(7)del(7)(p21)del(7)(q31),
+der(8)t(8;8)(p23;q22)x2,+der(8)t(4;8)(?;q11),der(9)t(9;20)(q13;q11.2),
+der(9)t(9;20)(q13;q11.2),der(10)t(5;10)(?;p11)x2,+der(10)ins(5)
dup(10)(q22),+del(11)(q2?1),+der(11)t(3;11)(?;q21),13,14,+15,+der(15)
t(15;16)(p10;p10)x2,16,der(17)t(17;22)(p12;q12)x2,+der(17)del(17)
(q11)t(11;17)(?;p13),18,+18,19,+der(19)del(19)(p13)del(19)(q13),20,
del(20)(q11),21,+22,+22,+22,+del(22)(q12)[cp12]*
LNM, lymph node metastasis found; NED, no evidence of disease; D, died.
*G-banding and SKY analyses.
yG-banding analysis.
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DNA and RNA Extraction
DNA and total RNA were extracted from snap-frozen
samples of 10 primary tumors and 4 cell line cultures, using
Puregene DNA Isolation Kit (Gentra Systems, Inc., Minne-
apolis, MN) and Tri Reagent (Sigma-Aldrich, St. Louis, MO),
according to the manufacturer’s instructions, respectively.
RNA quality was determined based on OD260/280 for all RNA
samples. Optical density at 260 and 280 nm was measured,
and all ratios calculated were within 1.75 to 1.93.
Array-Based CGH Analysis
Detection of gene amplification by array-based CGH was
performed using Vysis GenoSensor system (Abbott Vysis,
Inc., Downers Grove, IL), according to the manufacturer’s
instructions as described previously [19]. Briefly, test DNA
and normal reference DNA were labeled by random priming
to incorporate fluorophores and were hybridized to either
the AmpliOnc I microarray (Abbott Vysis Inc., Downers
Grove, IL, USA) containing 59 probes (P1, PAC, or BAC
clones) corresponding to 57 different oncogenes, or to the
GenoSensor Array 300 microarray (Vysis, Inc.) containing
287 genomic clones, including tumor-suppressor genes,
telomeres, and additional selected loci representing each
chromosome arm. The lists of targets on the microarrays are
available at www.vysis.com. Hybridization signal images in
three colors [4V,6-diamidino-2-phenylindole (DAPI), Cy3, and
Cy5 (or Alexa488 and Alexa594 for the AmpliOnc I micro-
array)] and their values were then analyzed by the Geno-
Sensor Reader System.
Fluorescent In Situ Hybridization (FISH) Analysis
BAC clones were purchased from CHORI (BACPAC
Resources, Oakland, CA) and were used as FISH probes.
The following clones contained the corresponding genes:
RPCI-1 118J21 for MYCL1 gene (clone cytogenetic locus,
1p34.1–p35.3), RPCI-11 181K3 for LAMC1/LAMC2 (1q25–
q31), RPCI-11 350N15 for FGFR1 (8p11.1–p11.21), RPCI-11
635N3 for p21-activated kinase-1 (PAK1; 11q13–q14), RPCI-
11 571M6 for CDK4/SAS (12q13–q14), RPCI-11 772E1 for
GLI (12q13.2–q13.3), and RP11-89L15 and RP11-181D10
for FOXO1A (13q12.3–q14.12). Briefly, following extraction
and purification, DNA probes were directly labeled by nick
translation with SpectrumGreen dUTP (Vysis, Inc.) for the
PAK1 probe and with SpectrumOrange dUTP (Vysis, Inc.)
for the other probes. Chromosomal preparations on slide and
fluorescent probes were denatured at 73jC before overnight
hybridization at 37jC, followed by posthybridization washes
and chromosome counterstaining by Vectashield with DAPI
(Vector Laboratories, Burlingame, CA). Hybridization signals
were detected using corresponding filters on an Olympus B52
microscope (Olympus Life and Material Science, Hamburg,
Germany). Images were captured using a charge-coupled
device camera and Cytovision software (Applied Imaging,
Santa Clara, CA).
Reverse Transcription–Polymerase Chain Reaction (RT-PCR)
RNA was DNase-treated using the DNA-free kit (Ambion,
Inc.), according to manufacturer’s protocol. Complementary
DNA (cDNA) was synthesized from 1 Mg of total RNA using
100 U of Superscript II Reverse Transcriptase, 75 ng/ml
random hexanucleotides (Invitrogen, Carlsbad, CA), and
125 MM of each dNTP (Pharmacia, Uppsala, Sweden) in a
final volume of 10 Ml. RNA and primers were denatured at
70jC for 10 minutes, followed by reverse transcription at
42jC for 1 hour and termination at 90jC for 2 minutes.
Expression of the oncogenic fusion genePAX3–FOXO1A
or PAX7–FOXO1A (PAX3/7–FOXO1A) in RMS tumors was
detected using RT-PCR. Amplifications of both chimeric
fusion gene and FOXO1A (as control) transcripts were per-
formed as described previously [21].
Real-Time Quantitative RT-PCR
Expression levels of PAX3 (GI: 31563350), PAX7 (GI:
4505618), FOXO1A (GI: 9257221), and AURKA (GI:
38327561) genes were determined in RNA from primary
RMS tumors, cell lines, and normal controls. The primer se-
quences used for the amplification of each gene and the sizes
of the products generated were as follows:
PAX3: 5V-CTGCGTCTCCAAGATCCTGTG-3V (forward)
and 5V-CGGCCTCCTCCTCTTCACC-3V (reverse) gener-
ated a 269-bp fragment
PAX7: 5V-GCTCCGGGGCAGAACTACC-3V (forward)
and 5V-GCACGCGGCTAATCGAACTC-3V (reverse) gen-
erated a 436-bp fragment
FOXOX1A: 5V-GTGTAACCTGCTCACTAACC-3V (forward)
and 5V-CCGCCTGACCCAAGTGAAG-3V (reverse) gener-
ated a 331-bp fragment
AURKA 5V-GGACCGATCTAAAGAAAACTGC-3V (forward)
and 5V-CTTTCCTTTACCCAGAGGGCG-3V (reverse) gen-
erated a 428-bp fragment
for GAPDH: 5V-CCAGAACATCATCCCTGC-3V (forward)
and 5V-GGAAGGCCATGCCAGTGAGC-3V (reverse) gen-
erated a 96-bp fragment.
All primers were exon-spanning (Sigma-Genosys Ltd.,
Rehovot, Israel).
Quantitative expression analysis was performed using
LightCycler Technology and SYBR Green kit, according to
the manufacturer’s instructions (Roche Diagnostics, Man-
nheim, Germany). Quantitative RT-PCR was performed in a
total volume of 10 ml using LightCycler FastStart DNA Master
SYBRGreen I (RocheDiagnostics) with 50 nMof each primer
(Sigma-Genosys Ltd.), 3 mM MgCl2, and 5% dimethyl sulf-
oxide only in the PAX3 and PAX7 reactions. All PCR con-
ditions included a preincubation step of 10 minutes at 95jC,
followed by 45 cycles. Each cycle consisted of denaturation
at 95jC for 10 seconds, annealing at specific temperatures
for 5 seconds, elongation at 72jC for 11 to 18 seconds,
and fluorescence measurement at specific temperatures for
5 seconds (specific reaction conditions are available on re-
quest). The final PCR cycle was followed by a melting curve
analysis to assess product specificity. Reaction efficiency
was determined for all quantitative RT-PCRs. The slope of
the standard curve was determined for each reaction, and
only the results from RT-PCR with slopes ranging between
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3.3 and 3.4 were included. Each experiment was per-
formed in duplicate; amplified products were checked by
electrophoresis on ethidium bromide–stained agarose gels
and sequenced to confirm their identity using BigDye Termi-
nator v. 1.1 on an ABI PRISM 310 Genetic Analyzer (Applied
Biosystems, Foster City, CA).
A standard curve was plotted for each gene and for the
GAPDH gene that served as a reference gene, using serial
dilution of cDNA. Log concentrations of the gene (X ) and of
GAPDH were calculated from the standard curve using
LightCycler 5.1 software (Roche Applied Science, Mann-
heim, Germany). The quantification procedure was as fol-
lows: in each tumor, the expression level of each gene (RX)
was calculated relative to GAPDH expression. The relative
expression value of the specific gene (X) in each specimen
([X/GAPDH]RMS) was compared to the average expression
obtained from the four normal skeletal muscle control RNA
samples ([X/GAPDH]average controls). The final results, termed
RX, were determined by the equation:
RX ¼ ½X=GAPDHRMS½X=GAPDHaverage controls
where RX values equal to or greater than a 1.5-fold change
are overexpressions, and RX values equal to or less than a
0.5-fold change are underexpressions. For each gene, rep-
resentative graphs of relative expression were constructed
with Prism software (GraphPad Software, San Diego, CA).
Results
Cytogenetic Analysis of Primary RMS Tumors
Table 1 describes patients’ clinical characteristics and the
cytogenetic analyses of the 10 primary RMS tumors. ERMS1
tumor cells demonstrated a modal number ranging from
pseudodiploid to hyperdiploid, with trisomies, chromosome
losses, and translocations that have been described pre-
viously in ERMS tumors [9,13,22]. ERMS2 was resected fol-
lowing both chemotherapy and radiotherapy, and displayed
a complex pseudodiploid karyotype of several clones involv-
ing numerical and structural aberrations of chromosomes 1,
2, 4, 5, 8, and 11 (Table 1).
Three of 10 ARMS tumors examined (ARMS3, ARMS4,
and ARMS7) demonstrated normal G-band karyotypes. It is
possible that contamination by adjacent normal cells may
explain these normal karyotypes or that non-neoplastic cells
may have a selective advantage and thus prevail over neo-
plastic cells. Thus, a normal G-band karyotype does not
necessarily rule out the neoplastic nature of the sample, as
previously reported [12,13,22,23]. All other ARMS tumors
tested displayed abnormal karyotypes. The cytogenetic
aberrations detected in both ARMS2 and ARMS6 tumors
were chromosomal polysomies without structural altera-
tions apart from dmins. ARMS2 revealed a tetraploid content
(Figure 1A), whereas ARMS6 demonstrated different levels
of polysomies in a tetraploid karyotype (Figure 1B). In addi-
tion to numerical changes, dmins were detected in these
four ARMS tumors. SKY analyses classified dmins as origi-
nating from chromosome 13 in ARMS2 and ARMS5 (Fig-
ure 1, A and C, respectively), from chromosome 1 in ARMS6
(Figure 1B), and from chromosome 3 in ARMS1 (Figure 1D).
ARMS1 and ARMS5 tumor cells with tetraploidy and dmins
displayed various translocations detailed in Table 1.
It is worth noting that none of the characteristic ARMS
translocations [t(1;13)(p36;q14) or t(2;13)(q35;q14)] was
cytogenetically detected by either G-banding or SKY analy-
ses in the ARMS tumors examined here. However, break-
points at 13q14 region, which harbors the FOXO1A gene,
were seen in two samples ARMS1 and ARMS5 (Table 1).
The ARMS5 tumor demonstrated a novel translocation of
the 13q14-ter region with a chromosome 20q13.1 band in
tetraploid. This translocation may be reciprocal and appears
as the sole structural alteration detected in this case along
with dmins (Figure 1C). The karyotype of ARMS1 tumor cells
was hypotetraploid and complex, involving numerical and
structural alterations (Figure 1D). The 13q14 locus was re-
arranged, but the reciprocal and counterpart translocant
was not detectable by either G-banding or SKY painting.
To date, only three karyotypes of PRMS tumors have
been published [22,24,25], whereas analysis of seven PRMS
samples using conventional CGH provided additional ge-
nomic data [7]. We present here G-banding and complemen-
tary SKY karyotype descriptions of a PRMS tumor obtained
at the time of diagnosis (PRMS1; Table 1 and Figure 1E ).
This chromosomal analysis demonstrated a hypertriploid
and complex karyotype with clonal evolution. The aberra-
tions involved all chromosomes, either numerically or struc-
turally, including multiple translocations, deletions, and
insertions (Table 1). Some of the gains and losses detected
here have been published previously, particularly gains of
chromosomes 5, 6q, 8, 18, and 22 and losses of 1q, 3, 13,
14, 15, and 17p [7,22,24,25].
Array-Based CGH Analysis Revealed Novel Gains
and Losses of Specific Genes
To identify genetic copy number changes associated with
RMS, tumor DNA was analyzed with AmpliOnc version I
(Abbott Vysis, Inc.) or Array 300 microarrays (AmpliOnc
version I was updated to Array 300 during the course of the
experiment). DNA from ARMS1, ARMS3, ARMS4, ARMS5,
ARMS7, and PRMS1were hybridizedwith AmpliOnc I, where-
as Array 300was used to analyzeDNA samples fromERMS1,
ERMS2, ARMS2, and ARMS6 tumors.
Borderline levels of copy number gain or loss were defined
for AmpliOnc I array, as previously described (0.77–1.26) [19].
Regarding Array 300, the mean G/R ratio value was 1.003,
and the standard deviation (SD) was 0.107, defining a mean
value of ±2 SD at the cutoff level of 0.78 to 1.22. Because
this range of values is within the range used for AmpliOnc I
analysis, cutoff values of 0.77 to 1.26 were designated to de-
termine the gain and loss levels for both array versions. Values
less than 0.77 were designated as losses. We further defined
two classes of gain: values with 1.26- to 2-fold change repre-
sented a mild increase in copy number, and changes greater
than 2-fold represented amplification. The genes that were
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either gained (mild increase or amplification) or lost in RMS
tumors are summarized in Table 2.
Array-based CGH results were further correlated with
cytogenetic analyses of tumor cells and were consistent with
ERMS1 for gains of chromosomes 2, 11q, and 19q and
for losses of 17p and 22q, and with ARMS6 for gains of
chromosome regions 8ptel, 8q24-ter, 12q12–13.3, and 22q.
In other cases, involvement of large chromosomal loci was
Figure 1. SKY analyses of primary RMS tumors. (A) ARMS2 sample demonstrated tetraploidy and dmins classified as chromosome 13. (B) ARMS6 cells displayed
dmins originating from chromosome 1 in a hypertetraploid karyotype. (C) ARMS5 presented a novel rearrangement between 13q14 and 20q13 and dmins classified
as originating from chromosome 13. The trisomies of chromosomes 10 and 21 shown here are not clonal. (D) ARMS1 tumor cells display a structural re-
arrangement at the 13q14 region and two dmins from chromosome 3 in a complex hypotetraploid karyotype. (E) Representative SKY image of the pleomorphic
RMS tumor (PRMS1) demonstrating multiple numerical and structural alterations in a hypertriploid karyotype involving all chromosomes (see also Table 1).
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depicted only from array-based CGH results: the ERMS2
tumor demonstrated a gain of chromosomes 1 and 20 with a
loss of chromosomes 3 and 9p12–q21; ARMS3 displayed a
gain of 20q; and DNA from ARMS7 revealed a gain of the
17q21–23 chromosomal region.
Array-basedCGHanalysis detected copy number changes
in genes related to multiple functional classes. Some of the
genes identified in our series encode or interact with tran-
scription factors. A mild increase in copy number and ampli-
fications of the three members of the MYC family were
detected:MYCN in ARMS7, and bothMYC andMYC-related
gene from lung cancer (MYCL1) genes in ARMS6. The co-
amplification of SAS/CDK4 and GLI genes was detected
in the ARMS5 tumor. Gain of SAS/CDK4 and loss of GLI
were identified in ARMS6 and PRMS1 samples, respectively.
A mild increase in the copy number of the CBFA2 gene in
ARMS7 and of the CDK2 gene in ARMS6 was also detected.
Loss of another transcription factor, the HIC1 gene, was
detected in ERMS1. Finally, a mild increase in the copy num-
ber of CCND2 in both ARMS3 and ARMS7 samples was
also found.
Changes in copy number were also detected in genes that
encode protein members of signaling pathways, including
ligands of cell surface receptors TGFB2 (in ERMS2), PDGFB
Table 2. Copy Number Changes of Specific Genes in RMS Tumors Detected by Array-Based CGH and FISH Analyses.
Case Array-Based CGH Results (Gene, Location, and Fold Change) FISH Results
Number
Mild Increase Amplification Loss Gene Number
Gene Designation
(Cytogenetic Locus)
Fold
Change
Gene Designation
(Cytogenetic Locus)
Fold
Change
Gene Designation
(Cytogenetic Locus)
Fold Change
Designation of Signals
per Cell
ERMS1 MSH2* (2p22.3–p22.1) 1.30 AKT2* (19q13.1–q13.2) 2.40 82M15* (17ptel) 0.75
GARP (11q13.5–q14) 1.30 WI-14673* (17ptel) 0.77
HIC1* (17p13.3) 0.74
D17S125* (17p12–p11.2) 0.74
22QTEL31* (22qtel) 0.76
ERMS2 FGR (1p36.2–1) 1.28 Chr 3 0.73–0.77 LAMC2 3–4
STS* (1q21) 1.65 PAK1 2–3
LAMC2 (1q25–q31) 1.33 Two STS probes* (9p11.2) 0.66
TGFB2* (1q41) 1.37
Tel probe* (1qtel) 1.30
AIB1 (20q12) 1.30
TNFRSF6B* (20q13) 1.31
TOM* (20qtel) 1.33
ARMS1 PAK1 (11q13.5–q14) 1.26 LAMC2 6
PAK1 4–10
ARMS2 PDGFB (22q13.1) 1.40 LAMC2 4
ARMS3 CCND2 (12p13) 1.28 PDGFRA (4q12) 0.73
AIB1 (20q12) 1.33
PTPN1 (20q13.1–q13.2) 1.36
ARMS4 No change
ARMS5 GLI (12q13.2–q13.3) 2.5 GLI 7–8
SAS/CDK4 (12q13.3) 3.2 SAS/CDK4 10–12
ARMS6 CSF1R* (5q33–35) 1.27 MYCL1 (1p34.3) 6.62 Two tel probes* (4qtel) 0.75 MYCL1 8
Two tel probes* (8ptel) 1.38 LAMC2 4
MYC (8q24.12–13) 1.34
PTK2 (8q24-ter) 1.79
Two tel probes* (10qtel) 1.78
WNT1 (12q12–q13) 1.44
CDK2 (12q13) 1.30
ERBB3* (12q13) 1.30
SAS/CDK4 (12q13.3) 1.29
AKT2* (19q13.1–2) 1.30
Chr 22 1.35–1.73
ARMS7 FGR (1p36.2–36.1) 1.71 HRAS (11p15.5) 0.74 LAMC2 2
LAMC2 (1q25–q31) 1.41 PAK1 2
MYCN (2p24.1) 1.51
RAF1 (3p25) 1.42
PAK1 (11q13.5–14) 1.56
CCND2 (12p13 ) 1.48
ERBB2 (17q21.2) 1.43
D17S1670 (17q23) 1.29
CBFA2 (21q22.3) 1.33
PRMS1 LAMC2 (1q25–q31) 1.27 FGFR1 (8p11.2–p11.1) 14.0 GLI (12q13.2–q13.3) 0.72 LAMC2 4
PAK1 (11q13.5–q14) 1.43 FGFR1 12–31
PAK1 6
STS, sequence-tagged site; tel, telomere; Chr, all probes on this chromosome were changed.
*Probes were represented only in the Array 300 microarray.
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(ARMS2), and WNT1 (ARMS6), and genes encoding tyro-
sine kinase receptors ErbB2 (ARMS7), ErbB3 (ARMS6),
TNFRSF6B (ERMS2), CSF1R (ARMS6), and FGFR1
(PRMS1). A mild increase in the copy number of genes in-
volved in mitogen-activated protein kinase cascade and
other cell signaling proteins was also identified in our series,
including RAF1 (ARMS7), FGR (ERMS2 and ARMS7),
AKT2 (ERMS1 and ARMS6), PTK2 (ARMS6), and PTPN1
(ARMS3). Conversely, the PDGFRA and HRAS genes were
deleted in ARMS3 and ARMS7, respectively. A mild increase
in copy number was also detected in two genes belonging to
the steroid receptor superfamily, which are involved in cellu-
lar signaling (the AIB1 gene in both ERMS2 and ARMS3
tumors and the TOM gene in ERMS2 tumor).
Amild increase in the copy number changes of two genes,
laminin g-2 (LAMC2) and PAK1, both involved in basal
membrane organization and cytoskeletal elements was
detected in four RMS samples (ERMS2, ARMS1, ARMS7,
and PRMS1; Table 2). FISH analysis was implemented to
validate the amplification of genes with a > 2-fold increase in
array-based CGH analysis and to validate the mild increase
in the copy number of LAMC2 and PAK1 genes detected in
three RMS samples each (Table 2). Fluorescent probes for
specific genes were used; fluorescent signals were counted
in 30 interphases in each analysis. The results are summa-
rized in Table 2 and are illustrated in Figure 2, A–D. Good
concordance was obtained between array-based CGH and
FISH results, except for ARMS7,which displayed an increase
in the copy number changes of several genes (Table 2),
whereas tumor cell culture demonstrated normal karyotype
(Table 1). SAS/CDK4 (Figure 2A) and GLI (Figure 2B)
amplifications in ARMS5 cells were confirmed. An increased
copy number of LAMC2 and PAK1 was detected by FISH
in ERMS2 and PRMS1 cells (Table 2) and in ARMS1
(Figure 2C), and the amplification of MYCL1 in ARMS6 cells
(Figure 2D) was also validated and confirmed.
Expression Analysis of PAX3, PAX7, FOXO1A,
and AURKA Genes in Primary RMS Tumors
RT-PCRand quantitative RT-PCRwere performed inRNA
extracted from the 10 primary tumors and the 4 cell lines.
RT-PCR detected PAX3–FOXO1A or PAX7–FOXO1A fu-
sion transcripts in 6 of 10 primary tumors (ERMS2, ARMS2,
ARMS3, ARMS4, ARMS5, andARMS7) and in theRMZ-RC2
and RH28 cell lines, as previously described [26,27].
Primer pair sequences for quantitative RT-PCR were
designed to amplify a part of the binding domains of PAX3
and PAX7 genes and a part of the transcriptional activation
domain of FOXO1A gene. Therefore, the expression levels
of each gene represented the sum of the expression de-
tected from both the wild type and the fusion genes. The
relative expression levels of these genes are presented in
Figure 3, A–C, respectively, and were further correlated
with RMS tumor subtypes (ERMS, ARMS, or PRMS) and
with the presence of PAX3/7–FOXO1A chimeric transcripts.
PAX3 and PAX7 genes were overexpressed in three of
four embryonal RMS samples tested (ERMS1, ERMS2, and
RD), with higher values in the two RMS samples ERMS1 and
RD that did not express the fusion transcript. Generally,
PAX7 expression values were higher than PAX3 values.
The FOXO1A gene was overexpressed in ERMS1 and was
underexpressed in the three other RMS samples tested.
Overexpression of PAX3 and/or PAX7 genes was
detected in all of the primary alveolar subtype tumors, except
for the ARMS1 sample that did not express the oncogenic
fusion gene PAX3/7–FOXO1A. FOXO1A overexpression
was seen in four of seven primary ARMS tumors tested,
but not in the ARMS1 sample mentioned above and not in
an additional sample that expressed the fusion oncogene
(ARMS5). In cell line samples, overexpression of PAX7 was
detected only in RMZ-RC2, which harbors the PAX7–
FOXO1A translocation [26], and PAX3 overexpression was
detected in the RH28 cell line, which harbors PAX3–
FOXO1A translocation [27].
The PRMS tumor that did not express PAX3/7–FOXO1A
transcripts demonstrated an overexpression of PAX3 and
FOXO1A genes.
The AURKA gene was overexpressed in all of the RMS
samples (Figure 3D). In primary RMS tumors, the highest
overexpression values (103- to 1030-fold change) were
detected in five samples that exhibited either complex kar-
yotypes (ERMS1, ERMS2, and ARMS1) or tetraploid karyo-
types (ARMS2 and ARMS5). All four RMS cell lines tested,
which were already shown to carry aneuploidy [23,26–28],
also demonstrated overexpression of the AURKA gene. It
Figure 2. Interphase FISH analyses of primary RMS tumor cells with specific
BAC and PAC clones confirmed the increased copy number change de-
tected by array-based CGH analysis: ARMS5 tumor cells hybridized with
SAS/CDK4 (A) and GLI (B) probes. LAMC2 (C; red) and PAK1 (C; green)
signals were detected in ARMS1 cells. (D) Hybridization of ARMS6 cells with
the MYCL1 probe.
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Figure 3. Quantitative RT-PCR expression analysis of primary RMS tumors and cell lines relative to average expression in normal skeletal muscle controls: (A)
PAX3, (B) PAX7 (C), FOXO1A, and (D) AURKA genes. Relative expression values are calculated in log scale and are presented above each bar.
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is worth noting that the lowest overexpression value of
AURKA (15-fold change) was detected in the adult-type
PRMS1 sample.
Discussion
Our complete spectral karyotyping, combined with array-
based CGH and expression analysis of fresh tissues ob-
tained from primary RMS tumors, revealed novel genomic
aberrations and altered gene expressions. Such analyses
have been reported on cell lines in the past [28,29] and on
two primary RMS using G-band, RT-PCR, and conventional
CGH recently [30].
Spectral analysis defined the origin of dmins from chro-
mosomes 1 and 13, and a novel translocation between
the 13q14 and 20q13.1 chromosomal regions. The multiple
chromosomal aberrations identified in the PRMS sample
enhance published cytogenetic data and further suggest
candidate loci associated with the development and pro-
gression of this rare adult RMS subtype. Our analysis also
emphasizes the chromosomal instability of RMS cells, in-
cluding aneuploidy (mostly tetraploidy), multiple structural
alterations, and dmins.
AURKA, a serine–threonine kinase, has been implicated
in the regulation of centrosome function, spindle assembly,
spindle maintenance, chromosome segregation, and cyto-
kinesis [31]. Alterations in its activity affect genomic stability
and disrupt the fidelity of centrosome duplication, resulting in
tetraploidization [32]. AURKA was therefore implicated as
a potent oncogene that induces cellular transformation [33].
AURKA amplification and/or overexpression was found in
a series of cancer cell lines and primary tumors, such as
breast, prostate, colorectal, and pancreatic tumors, and was
associated with grades of tumor differentiation and inva-
sive capability [34–37]. The high level of aneuploidy, in
particular the tetraploid pattern detected in four RMS sam-
ples, led us to hypothesize that AURKA may also play a role
in RMS tumorigenesis. Of note, AURKA overexpression
was not accompanied here by gene amplification, as de-
picted by array-based CGH analysis. The demonstration of
AURKA overexpression in all primary RMS tumors and
cell lines tested suggests a novel association between this
gene and the chromosomal instability in RMS, and may
propose a therapeutic role for AURKA inhibitors in the treat-
ment of this skeletal muscle neoplasm [38]. Other genes
belonging to the mitotic spindle checkpoint complex may
also be involved in RMS. For example, somatic mutations
were recently detected in the BUB1B gene in familial ERMS
cases [39], further suggesting an important role for regu-
lators of mitosis in the chromosomal instability detected
in RMS.
The association between PAX3, PAX7, and FOXO1A
genes and RMS is well established [10] and further charac-
terized in our RMS tumor samples. Because oncogenic
PAX3/7–FOXO1A fusions were not detected by either cyto-
genetic or RT-PCR analyses in 4 of 10 primary tumors exam-
ined, expression analyses of these genes were performed.
We confirmed previously published data and demonstrated
that overexpression of PAX3 and PAX7 does not necessarily
correlate with the detection of the chimeric fusion transcript
PAX3–FOXO1A or PAX7–FOXO1A, suggesting that mech-
anisms other than oncogenic fusion cause changes in the
expression patterns of these genes [11]. One example is the
ARMS6 tumor that demonstrated only PAX3 overexpression
(14-fold), without overexpression of PAX7 or FOXO1A, and
did not express fusion transcripts. Of note, the embryonal
ERMS2 tumor sample demonstrated the PAX3/7–FOXO1A
fusion transcript that is characteristic of the alveolar RMS
subtype. It is possible that this transcript resulted from prior
chemotherapy and radiotherapy of this patient; however,
previous cytogenetic analyses in both an ERMS cell line
[40] and a primary ERMS tumor [41] have demonstrated
translocations of the 2q35 locus that harbors PAX3, and
fusions of PAX3/7–FOXO1A have been detected by either
cytogenetic, FISH, or RT-PCR analyses in embryonal RMS
samples [11,42]. Furthermore, we did not detect either fu-
sion transcripts or overexpression of PAX3 or PAX7 in the
primary ARMS1 and in the A-204 ERMS cell line. These
findings suggest that RMS transformation is not absolutely
dependent on the abnormal expression of the chimeric
PAX3–FOXO1A or PAX7–FOXO1A transcripts, and might
be initiated and propagated by other genetic changes. This
idea is further supported by PAX3–FOXO1A knockin studies
in mice, which demonstrated that oncogenic fusion is not
sufficient for tumor development [43].
Array-based CGH is a powerful tool for the rapid and
accurate detection of specific gene copy number changes,
allowing the identification of novel candidate genes in carci-
nogenesis [19,44]. Using array-based CGH analysis, mul-
tiple copy number changes were detected in our RMS series.
By comparison, in six Wilms tumor samples, array-based
CGH analyses detected only one amplification event in the
MRP1 gene [19], and no amplifications or deletions were
seen in 8 synovial sarcoma and 20 Ewing sarcoma samples
analyzed in our laboratory with the same arrays (A. Bar-
Shira and A. Orr-Urtreger, personal communication). Our
data therefore suggest that RMS tumorigenesis involves
multiple amplification or deletion events in several gene fam-
ilies and the disruption of a number of cellular pathways.
The involvement of the MYC transcription factor family,
particularlyMYCN, has been reported in RMS tumorigenesis
[45,46]. We detected the novel amplification of MYCL1
gene in RMS, which has already been demonstrated in
other neoplasms, including small cell lung cancer [47] and
hormone-resistant prostate cancer [48]. Additional changes
in genes encoding for transcription factors (such as the
amplification ofGLI and the mild increase in the copy number
of CBFA2, and the overexpression of PAX3 and PAX7) were
also observed in our study and reported in RMS tumori-
genesis [3,11], suggesting that the disruption of the tran-
scriptional machinery is a major event in RMS cells, which
likely leads to the abnormal expression of multiple down-
stream target genes.
Using array-based CGH and FISH analyses, we detected
amild increase in the copy number of genes implicated in cell-
to-cell contact, cell adhesion, and motility, including WNT1,
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FGR, PTK2, TGFB2, and AIB1. Gain in the copy number of
LAMC2 and PAK1, both related to basal membrane organi-
zation and cytoskeletal elements, was identified in three
primary RMS tumors each, suggesting a novel association
between these genes and RMS tumorigenesis.
The p21-activated kinase PAK1 is one of the critical
effectors linking the small GTPases Rac1 and Cdc42 to
cytoskeleton-dependent cell functions [49]. Overexpression
of PAK1 in cancer cells increases cell migration potential
and anchorage-independent growth [50]. To date, PAK1 func-
tion has not been directly related to myogenesis or RMS.
However, studies on RMS cell lines have demonstrated
constitutive activation of Rac1 and Cdc42, which appears
to elicit the loss of cell contact inhibition and anchorage-
dependent growth, possibly contributing to transformation of
myoblastic cells, inhibition of myoblast differentiation, and
impaired exit of myoblasts from cell cycle [51–53]. Recently,
gene expression profiling of primary RMS tumors demon-
strated Rac1 overexpression [18]. The increased copy num-
ber of PAK1 in primary RMS tumors may therefore be linked
to these abnormal myoblast functions during tumorigenesis.
The composition of extracellular matrix components influ-
ences differentiation and myogenesis [54]. LAMC2 encodes
the g polypeptide chain specific to laminin (LN)5, an extra-
cellular matrix protein that forms anchoring filaments, con-
tributing to the structural and biologic relationships between
the epithelium and the stroma. The g chain is of importance
in outside-in and inside-out cell signaling, which sustain cell-
to-cell contact and cell adhesion [55]. LN5, particularly the g
chain, is associated with cancer aggressiveness [56]. LN5
expression enhances the tumorigenicity of a human fibro-
sarcoma cell line, suggesting that it may also promote tumor
growth in vivo [57]. Overexpression of LAMC2 was also
linked to tumor invasion and unfavorable outcomes in breast
and colon carcinomas, although the mechanism(s) associ-
ating LAMC2 overexpression to cancer progression remains
unclear [57–59]. Increased LAMC2 copy number in three of
the RMS samples tested here may suggest its involvement in
the disruption of cell adhesion and RMS progression.
Of note, although some of the alterations, such as
AURKA overexpression, are described here in all primary
RMS tumor samples, others (including LAMC2 and PAK1
copy number increase) were observed in only a few samples.
Overall data emphasize the molecular differences underlying
RMS tumors, and may also explain the variable outcome of
individual patients. It is also worth noting that, although the
samples studied were from primary tumors, specific genetic
alterations described here, which may lead to the dys-
regulation of a given gene, are not sufficient to establish
their causality in RMS and do not prove whether or not they
are essential to RMS tumorigenesis.
In summary, cytogenetic andmolecular analyses of 10 pri-
mary RMS tumors have demonstrated the complexity of the
genetic mechanisms underlying the development of this
neoplasm. The novel detection of AURKA overexpression
suggests an association between the spindle mitotic check-
point complex and the chromosomal instability and aneu-
ploidy frequently seen in RMS. The copy number gain of
LAMC2 and PAK1, in addition to other genes involved in cell
contact and migration, may implicate the disruption of these
functions and the abnormal progression of myogenesis in
RMS tumorigenesis. Together, these altered pathways may
interact with one another, in the cell matrix, and through
intracellular signaling, influencing the transcriptional ma-
chinery and mitotic complexes and ultimately contributing
to RMS malignant transformation and metastasis.
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